© Reuters.
By Daniel Shvartsman
Investing.com — Stocks in focus in pre-market trade on Tuesday, December 28th. Prices as of 8:30am ET, please refresh to see updated pricing.
- Tesla (NASDAQ:) traded up 1.8% after getting a price target hike from both Wedbush and Argus gave the electric vehicle leader another charge. Wedbush’s Daniel Ives the EV sector is set for a significant step forward and Tesla’s navigation of the semiconductor supply chain issues puts it in a position of strength. It’s not all sunshine for EV related companies, with Lucid Group Inc (NASDAQ:)down 1.2% pre-market.
- Nvidia (NASDAQ:) and AMD appear poised to lead semiconductors higher again, as they are trading up 1.4% and 1.2% respectively in the pre-market session.
- Apple (NASDAQ:) is also up .2% in pre-market trading despite . The tech leader is just off of both all-time highs and the shiny $3 Trillion market cap barrier.
- Albemarle Corp (NYSE:) is up nearly 2% and MercadoLibre Inc (NASDAQ:) is up 1.5%.
- Peloton Interactive Inc (NASDAQ:) is on watch after a Raymond James analyst called this fiscal year’s guidance aggressive even after the most recent quarter’s drop. Aaron Kessler said there was “continued softness in the December quarter”, and rates Peloton a Market Perform.
- F5 Networks Inc (NASDAQ:) is up 1% in thin trading after Needham & Company in networking for 2022, raising the price target to $303 from $266 (and the current share price of $245). Alex Henderson lauded the company’s software transition and said it was “becoming a Cloud/Kubernetes play” that would merit a higher multiple.
- BiondVax Pharmaceuticals Ltd ADR (NASDAQ:) is poised to rebound from yesterday’s share offering induced sell-off, as it is up 38% in busy pre-market trading.
- Mercury Systems Inc (NASDAQ:) looks set to open higher after announcing the adoption of a “poison pill” shareholder rights plan in response to activist Jana Partners’ 6.6% .
- Vipshop Holdings Limited (NYSE:) was down 2.2% after for the current quarter.
- Kiniksa Pharmaceuticals Ltd (NASDAQ:) is down 16% pre-market after its Phase 3 trial of mavrilimumab as a treatment for Covid-19 related acute respiratory syndrome did not meet the primary efficacy endpoint.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment